CARDIFF ONCOLOGY, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
CARDIFF ONCOLOGY, INC. (CRDF) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $6.10 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-12.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2015-03-12
- CARDIFF ONCOLOGY, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was $6.10M, a 38.65% increase from fiscal 2013.
- CARDIFF ONCOLOGY, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $4.40M, a 120.81% increase from fiscal 2012.
- CARDIFF ONCOLOGY, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2012 was $1.99M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2014-12-31 | $6.10M 10-K · filed 2015-03-12 |
| 2013-12-31 | $4.40M 10-K · filed 2015-03-12 |
| 2012-12-31 | $1.99M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |